Parasto Baghae Pour, S. Gregg, K. Coakley, L. F. Caffey, D. Cohen, O. Myers, D. Gonzales-Pacheco
{"title":"The Use of the RELiZORB Immobilized Lipase Cartridge in Enterally-Fed Children With Cystic Fibrosis","authors":"Parasto Baghae Pour, S. Gregg, K. Coakley, L. F. Caffey, D. Cohen, O. Myers, D. Gonzales-Pacheco","doi":"10.1097/TIN.0000000000000300","DOIUrl":null,"url":null,"abstract":"The objective of this retrospective study was to evaluate the impact of the RELiZORB immobilized lipase cartridge with overnight enteral nutrition (EN) on body mass index (BMI) or weight-for-length percentile, stool quality, and gastrointestinal (GI) symptoms in children with cystic fibrosis (CF) and pancreatic insufficiency. Frequency of diarrhea, steatorrhea, and malodorous stools significantly decreased at final visit compared with baseline (P = .008, P = .004, P = .031, respectively). Improved BMI or weight-for-length percentile was observed in 10 out of 16 participants; however, the change was not significant. RELiZORB use decreased frequency of most GI symptoms in pediatric patients with CF on EN.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/TIN.0000000000000300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The objective of this retrospective study was to evaluate the impact of the RELiZORB immobilized lipase cartridge with overnight enteral nutrition (EN) on body mass index (BMI) or weight-for-length percentile, stool quality, and gastrointestinal (GI) symptoms in children with cystic fibrosis (CF) and pancreatic insufficiency. Frequency of diarrhea, steatorrhea, and malodorous stools significantly decreased at final visit compared with baseline (P = .008, P = .004, P = .031, respectively). Improved BMI or weight-for-length percentile was observed in 10 out of 16 participants; however, the change was not significant. RELiZORB use decreased frequency of most GI symptoms in pediatric patients with CF on EN.
本回顾性研究的目的是评估RELiZORB固定化脂肪酶药筒与夜间肠内营养(EN)对囊性纤维化(CF)和胰腺功能不全儿童体重指数(BMI)或体重长度百分位数、粪便质量和胃肠道(GI)症状的影响。与基线相比，最后一次就诊时腹泻、脂肪漏和恶臭便的频率显著降低(P = 0.008, P = 0.004, P = 0.031)。16名参与者中有10人的BMI或体重长度百分位数有所改善;然而，这种变化并不显著。使用RELiZORB可降低EN上CF患儿大多数胃肠道症状的发生频率。
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
